US5545553A
(en)
*
|
1994-09-26 |
1996-08-13 |
The Rockefeller University |
Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
|
BR9917026B1
(pt)
|
1998-12-09 |
2010-10-19 |
|
método para fabricar glicoproteìnas tendo glicosilação do tipo humano.
|
CA2389217C
(en)
|
1999-10-26 |
2016-12-06 |
Plant Research International B.V. |
Mammalian-type glycosylation in plants
|
DK1283265T3
(da)
*
|
2000-05-17 |
2009-11-09 |
Mitsubishi Tanabe Pharma Corp |
Fremgangsmåde til fremstilling af protein med reduktion af mannosephosphat i sukkerkæden og glycoprotein fremstillet derved
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US7795002B2
(en)
*
|
2000-06-28 |
2010-09-14 |
Glycofi, Inc. |
Production of galactosylated glycoproteins in lower eukaryotes
|
US7625756B2
(en)
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
US7598055B2
(en)
*
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
MXPA03000105A
(es)
|
2000-06-28 |
2004-09-13 |
Glycofi Inc |
Metodo para producir glicoproteinas modificadas.
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
US8697394B2
(en)
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
CA2411968C
(en)
*
|
2000-06-30 |
2009-12-15 |
Flanders Interuniversity Institute For Biotechnology (Vib) |
Protein glycosylation modification in pichia pastoris
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
DK1356068T3
(en)
|
2001-01-19 |
2015-02-16 |
Phyton Holdings Llc |
PROCESS FOR THE PRODUCTION OF secretory glycoprotein with HUMAN TYPE SUGAR CHAIN FOR USING A PLANT CELL
|
TWI377253B
(en)
|
2001-04-16 |
2012-11-21 |
Martek Biosciences Corp |
Product and process for transformation of thraustochytriales microorganisms
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7399613B2
(en)
*
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
ES2564688T3
(es)
|
2001-10-10 |
2016-03-28 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de poli(éter) a eritropoyetina
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7439043B2
(en)
*
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US7265085B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7157277B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
CN105131104B
(zh)
|
2001-10-10 |
2018-11-16 |
诺和诺德公司 |
肽的重构和糖缀合
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7297511B2
(en)
*
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
US7265084B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7473680B2
(en)
*
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
JP4820055B2
(ja)
|
2001-12-27 |
2011-11-24 |
グライコフィ, インコーポレイテッド |
哺乳動物型糖質構造を操作するための方法
|
US20060024292A1
(en)
*
|
2001-12-27 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
|
US20060034829A1
(en)
*
|
2001-12-27 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
|
US6964784B2
(en)
*
|
2002-03-07 |
2005-11-15 |
Optigenex, Inc. |
Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
|
NZ546945A
(en)
|
2002-03-19 |
2008-04-30 |
Plant Res Int Bv |
A plant host cell system for the expression of human GnTIII
|
WO2003078637A2
(en)
*
|
2002-03-19 |
2003-09-25 |
Plant Research International B.V. |
Optimizing glycan processing in plants
|
US7972809B2
(en)
|
2002-04-26 |
2011-07-05 |
National Institute Of Advanced Industrial Science & Technology |
Methylotrophic yeast producing mammalian type sugar chain
|
DE60336555D1
(de)
|
2002-06-21 |
2011-05-12 |
Novo Nordisk Healthcare Ag |
Pegylierte glykoformen von faktor vii
|
IL165717A0
(en)
*
|
2002-06-26 |
2006-01-15 |
Flanders Interuniversity Inst |
A strain of methylotrophic yeast for producing proteins
|
AU2003246286A1
(en)
*
|
2002-06-29 |
2004-01-19 |
Korea Research Institute Of Bioscience And Biotechnology |
Hansenula polymorpha mutant strains with defect in outer chain biosynthesis and the production of recombinant glycoproteins using the same strains
|
WO2004028545A1
(en)
*
|
2002-09-25 |
2004-04-08 |
Astrazeneca Ab |
A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
|
AR042145A1
(es)
|
2002-11-27 |
2005-06-08 |
Dow Agrociences Llc |
Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
|
RU2407796C2
(ru)
*
|
2003-01-22 |
2010-12-27 |
Гликарт Биотекнолоджи АГ |
КОНСТРУКЦИИ СЛИЯНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ С ПОВЫШЕННЫМИ АФФИННОСТЬЮ СВЯЗЫВАНИЯ Fc-РЕЦЕПТОРА И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
|
PL224786B1
(pl)
|
2003-01-22 |
2017-01-31 |
Glycart Biotechnology Ag |
Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
AU2012227297B2
(en)
*
|
2003-02-20 |
2013-11-14 |
Glycofi, Inc. |
Combinatorial DNA Library for Producing Modified N-Glycans in Lower Eukaryotes
|
BRPI0408358A
(pt)
|
2003-03-14 |
2006-03-21 |
Neose Technologies Inc |
polìmeros hidrossolúveis ramificados e seus conjugados
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
US7691603B2
(en)
*
|
2003-04-09 |
2010-04-06 |
Novo Nordisk A/S |
Intracellular formation of peptide conjugates
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
EP2338333B1
(de)
|
2003-04-09 |
2017-09-06 |
ratiopharm GmbH |
Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
|
ES2380093T3
(es)
|
2003-05-09 |
2012-05-08 |
Biogenerix Ag |
Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
WO2005042753A1
(en)
*
|
2003-10-28 |
2005-05-12 |
Chesapeake Perl, Inc. |
Production of human glycosylated proteins in transgenic insects
|
US9357755B2
(en)
*
|
2003-10-28 |
2016-06-07 |
The University Of Wyoming |
Production of human glycosylated proteins in silk worm
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US7507573B2
(en)
*
|
2003-11-14 |
2009-03-24 |
Vib, Vzw |
Modification of protein glycosylation in methylotrophic yeast
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
JP4719686B2
(ja)
*
|
2003-11-24 |
2011-07-06 |
バイオジェネリックス アーゲー |
GlycoPEG化エリスロポエチン
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US7956032B2
(en)
*
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20080318850A1
(en)
*
|
2003-12-03 |
2008-12-25 |
Neose Technologies, Inc. |
Glycopegylated Factor Ix
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
ES2528739T3
(es)
*
|
2003-12-24 |
2015-02-12 |
Glycofi, Inc. |
Métodos para eliminar la manosilfosforilación de glucanos en la producción de glucoproteínas
|
AU2005206796B2
(en)
|
2004-01-08 |
2011-06-16 |
Ratiopharm Gmbh |
O-linked glycosylation of peptides
|
KR100604994B1
(ko)
*
|
2004-01-30 |
2006-07-26 |
한국생명공학연구원 |
알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법
|
JP4932699B2
(ja)
*
|
2004-03-17 |
2012-05-16 |
グライコフィ, インコーポレイテッド |
真菌および酵母におけるシチジンモノホスフェート−シアル酸合成経路を操作する方法
|
US20050265988A1
(en)
*
|
2004-03-18 |
2005-12-01 |
Byung-Kwon Choi |
Glycosylated glucocerebrosidase expression in fungal hosts
|
EP1737969B2
(de)
*
|
2004-04-15 |
2018-09-12 |
GlycoFi, Inc. |
Produktion galaktosylierter glykoproteine in niederen eukaryonten
|
JP4954866B2
(ja)
*
|
2004-04-29 |
2012-06-20 |
グライコフィ, インコーポレイテッド |
糖タンパク質の作製においてアルファ−マンノシダーゼ抵抗性グリカンを減少させるか又は排除する方法
|
JP5752582B2
(ja)
*
|
2004-04-29 |
2015-07-22 |
グライコフィ, インコーポレイテッド |
糖タンパク質の作製においてアルファ−マンノシダーゼ抵抗性グリカンを減少させるか又は排除する方法
|
MXPA06012676A
(es)
*
|
2004-05-04 |
2007-04-02 |
Novo Nordisk Healthcare Ag |
Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos.
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
WO2006014725A1
(en)
*
|
2004-07-21 |
2006-02-09 |
Glycofi, Inc. |
IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlcNAcMAN5GLCNAC2 GLYCOFORM
|
WO2006026992A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Novozymes A/S |
Altered structure of n-glycans in a fungus
|
EP1799249A2
(de)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegyliertes interferon alpha
|
WO2006035057A1
(en)
*
|
2004-09-29 |
2006-04-06 |
Novo Nordisk Health Care Ag |
Modified proteins
|
JP5948627B2
(ja)
|
2004-10-29 |
2016-07-20 |
レイショファーム ゲーエムベーハー |
線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化
|
WO2006071856A2
(en)
*
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
EP2514757A3
(de)
|
2005-01-10 |
2014-03-05 |
ratiopharm GmbH |
Glycopegylierter Granulozyten-Kolonie stimulierende Faktor
|
CN101137757A
(zh)
*
|
2005-03-07 |
2008-03-05 |
植物研究国际公司 |
蘑菇的糖工程
|
EP1866427A4
(de)
*
|
2005-03-30 |
2010-09-01 |
Novo Nordisk As |
Herstellungsverfahren zur produktion von in insektenzelllinien entstandenen peptiden
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
EP1888098A2
(de)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glykopegylierte erythropoetin-formulierungen
|
EP1907421A4
(de)
*
|
2005-06-30 |
2012-03-28 |
Abbott Lab |
Il-12/p40-bindende proteine
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
AU2006280932A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Novo Nordisk A/S |
Glycopegylated factor VII and factor Vila
|
MY169746A
(en)
|
2005-08-19 |
2019-05-14 |
Abbvie Inc |
Dual variable domain immunoglobulin and uses thereof
|
EP2500356A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2620515A1
(en)
*
|
2005-09-02 |
2007-03-08 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
|
EP1937305A4
(de)
*
|
2005-09-09 |
2008-10-08 |
Glycofi Inc |
Immunglobulin, das vorwiegend eine man7glcnac2, man8glcnac2 glycoform enthält
|
CA2623197A1
(en)
*
|
2005-09-22 |
2007-03-29 |
Prosci Incorporated |
Glycosylated polypeptides produced in yeast mutants and methods of use thereof
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
KR101105718B1
(ko)
*
|
2005-10-27 |
2012-01-17 |
한국생명공학연구원 |
돌리칠 포스페이트 만노스 의존알파-1,3-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자와 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
AU2006316838B2
(en)
|
2005-11-15 |
2012-04-12 |
Glycofi, Inc |
Production of glycoproteins with reduced O-glycosylation
|
AU2006320392B2
(en)
|
2005-11-30 |
2013-01-17 |
AbbVie Deutschland GmbH & Co. KG |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
ES2527661T3
(es)
|
2005-11-30 |
2015-01-28 |
Abbvie Inc. |
Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
US7884264B2
(en)
*
|
2006-01-17 |
2011-02-08 |
Biolex Therapeutics, Inc. |
Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants
|
US20090181041A1
(en)
*
|
2006-01-23 |
2009-07-16 |
Jan Holgersson |
Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
WO2007132355A2
(en)
*
|
2006-01-26 |
2007-11-22 |
Recopharma Ab |
Compositions and methods for inhibiting viral adhesion
|
WO2007123801A1
(en)
*
|
2006-04-05 |
2007-11-01 |
Genencor International, Inc. |
Filamentous fungi having reduced udp-galactofuranose content
|
CN101472947A
(zh)
*
|
2006-04-21 |
2009-07-01 |
惠氏公司 |
用于高通量筛选细胞系的方法
|
EP2027271A4
(de)
*
|
2006-05-19 |
2010-06-09 |
Glycofi Inc |
Rekombinante vektoren
|
AU2007254141B2
(en)
*
|
2006-05-19 |
2012-10-11 |
Glycofi, Inc. |
Erythropoietin compositions
|
DK2019864T3
(da)
*
|
2006-05-24 |
2011-09-26 |
Univ Provence Aix Marseille 1 |
Fremstilling og anvendelser af gensekvenser, der koder for kimære glykosyltransferaser med optimeret glykosyleringsaktivitet
|
AR078117A1
(es)
|
2006-06-20 |
2011-10-19 |
Protech Pharma S A |
Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
|
WO2008011633A2
(en)
*
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
US7879799B2
(en)
*
|
2006-08-10 |
2011-02-01 |
Institute For Systems Biology |
Methods for characterizing glycoproteins and generating antibodies for same
|
CN101512008B
(zh)
*
|
2006-09-08 |
2015-04-01 |
艾伯维巴哈马有限公司 |
白介素-13结合蛋白
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
CA2665644A1
(en)
*
|
2006-10-12 |
2008-05-29 |
Genentech, Inc. |
Antibodies to lymphotoxin-alpha
|
EP1916259A1
(de)
|
2006-10-26 |
2008-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
|
WO2008073620A2
(en)
*
|
2006-11-02 |
2008-06-19 |
Neose Technologies, Inc. |
Manufacturing process for the production of polypeptides expressed in insect cell-lines
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
TW200833711A
(en)
*
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
FR2912154B1
(fr)
|
2007-02-02 |
2012-11-02 |
Glycode |
Levures genetiquement modifiees pour la production de glycoproteines homogenes
|
PL2148691T3
(pl)
|
2007-02-05 |
2015-12-31 |
Apellis Pharmaceuticals Inc |
Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
RU2479629C2
(ru)
*
|
2007-03-07 |
2013-04-20 |
Гликофи, Инк. |
Продукция гликопротеинов с модифицированным фукозилированием
|
DK3199180T3
(da)
|
2007-03-08 |
2022-03-21 |
Humanigen Inc |
Epha3-antistoffer til behandlingen af faste tumorer
|
HUE041818T2
(hu)
|
2007-03-22 |
2019-05-28 |
Biogen Ma Inc |
Kötõ proteinek, beleértve az antitesteket, CD154-et specifikusan kötõ antitest származékokat és antitest fragmenseket is, és alkalmazásaik
|
JP5967861B2
(ja)
|
2007-04-03 |
2016-08-10 |
オキシレイン ユーケー リミテッド |
分子のグリコシル化
|
KR20100016160A
(ko)
|
2007-04-03 |
2010-02-12 |
바이오제너릭스 에이지 |
글리코페길화 g―csf를 이용하는 치료 방법
|
US20080256056A1
(en)
*
|
2007-04-10 |
2008-10-16 |
Yahoo! Inc. |
System for building a data structure representing a network of users and advertisers
|
JP5485869B2
(ja)
|
2007-04-17 |
2014-05-07 |
スティヒティング ディーンスト ランドバウクンディフ オンデルズーク |
非哺乳動物グリコシルトランスフェラーゼの発現による植物における哺乳動物型グリコシル化反応
|
JP5575636B2
(ja)
|
2007-05-07 |
2014-08-20 |
メディミューン,エルエルシー |
抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
|
US20090053167A1
(en)
*
|
2007-05-14 |
2009-02-26 |
Neose Technologies, Inc. |
C-, S- and N-glycosylation of peptides
|
PT2068927E
(pt)
|
2007-05-14 |
2016-02-10 |
Medimmune Llc |
Métodos para reduzir os níveis de eosinófilos
|
US20090175847A1
(en)
*
|
2007-05-30 |
2009-07-09 |
Abbott Laboratories |
Humanized antibodies to ab (20-42) globulomer and uses thereof
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
JP5876649B2
(ja)
|
2007-06-12 |
2016-03-02 |
ラツィオファルム ゲーエムベーハーratiopharm GmbH |
ヌクレオチド糖の改良製造法
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
US8637435B2
(en)
*
|
2007-11-16 |
2014-01-28 |
Merck Sharp & Dohme Corp. |
Eukaryotic cell display systems
|
AU2008343972B2
(en)
|
2007-12-19 |
2014-07-03 |
Glycofi, Inc. |
Yeast strains for protein production
|
EP2240595B2
(de)
|
2008-01-03 |
2019-07-24 |
Cornell Research Foundation, Inc. |
Expression eines glycosylierten proteins in prokaryonten
|
JP2011514157A
(ja)
*
|
2008-02-20 |
2011-05-06 |
グライコフィ, インコーポレイテッド |
蛋白質生産用ベクター及び酵母株
|
WO2009108806A1
(en)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US8877686B2
(en)
*
|
2008-03-03 |
2014-11-04 |
Glycofi, Inc. |
Surface display of recombinant proteins in lower eukaryotes
|
EP2271669A1
(de)
*
|
2008-03-11 |
2011-01-12 |
Genentech, Inc. |
Antikörper mit verstärkter adcc-funktion
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US9296810B2
(en)
|
2008-05-02 |
2016-03-29 |
Novartis Ag |
Fibronectin-based binding molecules and uses thereof
|
NZ588713A
(en)
|
2008-05-09 |
2012-10-26 |
Abbott Gmbh & Co Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
CN102112150A
(zh)
*
|
2008-05-30 |
2011-06-29 |
格利科菲公司 |
用于生产具有末端α-1,3-连接的半乳糖的蛋白质的酵母菌株
|
BRPI0913366A8
(pt)
|
2008-06-03 |
2017-07-11 |
Abbott Lab |
Imunoglobulinas de domínio variável duplo e seus usos
|
TW201008580A
(en)
|
2008-06-03 |
2010-03-01 |
Abbott Lab |
Dual variable domain immunoglobulin and uses thereof
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
WO2010006059A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 binding proteins and uses thereof
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
DK2331701T3
(da)
|
2008-08-08 |
2013-06-24 |
Vib Vzw |
Celler, der danner glycoproteiner med ændrede glycosyleringsmønstre og fremgangsmåder dermed og anvendelse deraf
|
EP2324121B1
(de)
|
2008-08-12 |
2012-11-07 |
GlycoFi, Inc. |
Verbesserte vektoren und hefestämme zur proteinproduktion: ca2+-atpase-überexpression
|
EP2331110B1
(de)
|
2008-09-25 |
2013-08-28 |
Glycosyn LLC |
Zusammensetzungen und verfahren zur gentechnischen herstellung einer probiotischen hefe
|
JP5652206B2
(ja)
|
2008-10-01 |
2015-01-14 |
旭硝子株式会社 |
宿主、形質転換体およびその製造方法、ならびにo−グリコシド型糖鎖含有異種蛋白質の製造方法
|
EP2358392B1
(de)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antikörper-formulierung
|
JP2012510821A
(ja)
*
|
2008-12-04 |
2012-05-17 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
NZ593448A
(en)
|
2008-12-19 |
2012-06-29 |
Jennewein Biotechnologie Gmbh |
Synthesis of fucosylated compounds
|
WO2010071824A2
(en)
*
|
2008-12-19 |
2010-06-24 |
Momenta Pharmaceuticals, Inc. |
Methods related to modified glycans
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
KR20110110349A
(ko)
*
|
2009-01-29 |
2011-10-06 |
아보트 러보러터리즈 |
Il-1 결합 단백질
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
CA2751730A1
(en)
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
|
EP2772269A3
(de)
|
2009-03-05 |
2015-01-14 |
Abbvie Inc. |
IL-17-bindende Proteine
|
EA201101241A1
(ru)
|
2009-03-06 |
2012-04-30 |
Калобайос Фармасьютиклз, Инк. |
Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
KR20110129935A
(ko)
|
2009-03-16 |
2011-12-02 |
세파론 오스트레일리아 피티와이 엘티디 |
항종양 활성을 가진 인간화된 항체
|
CA3003188C
(en)
*
|
2009-03-16 |
2020-04-14 |
Dsm Ip Assets B.V. |
Protein production in microorganisms of the phylum labyrinthulomycota
|
WO2010112458A1
(en)
|
2009-03-31 |
2010-10-07 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
|
CN104725512A
(zh)
|
2009-04-27 |
2015-06-24 |
诺华股份有限公司 |
增加肌肉生长的组合物和方法
|
EP2435577A4
(de)
*
|
2009-05-26 |
2016-04-13 |
Momenta Pharmaceuticals Inc |
Herstellung von glykoproteinen
|
WO2010138184A2
(en)
*
|
2009-05-27 |
2010-12-02 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
WO2011011495A1
(en)
*
|
2009-07-24 |
2011-01-27 |
Merck Sharp & Dohme Corp. |
Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast
|
KR20120089659A
(ko)
|
2009-08-29 |
2012-08-13 |
아보트 러보러터리즈 |
치료용 dll4 결합 단백질
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
KR102000383B1
(ko)
|
2009-09-29 |
2019-07-15 |
유니버시테이트 젠트 |
만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
|
JP2013508292A
(ja)
|
2009-10-14 |
2013-03-07 |
カロバイオス ファーマシューティカルズ インコーポレイティッド |
EphA3に対する抗体
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
AU2010307098A1
(en)
|
2009-10-16 |
2012-04-26 |
Merck Sharp & Dohme Corp. |
Method for producing proteins in Pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
MX2012004993A
(es)
|
2009-10-30 |
2012-06-12 |
Merck Sharp & Dohme |
Metodos para la produccion de proteinas recombinantes con eficiencias de secrecion mejoradas.
|
AU2010313492B2
(en)
|
2009-10-30 |
2014-05-29 |
Merck Sharp & Dohme Corp. |
Method for producing therapeutic proteins in Pichia pastoris lacking dipeptidyl aminopeptidase activity
|
EP2494050A4
(de)
*
|
2009-10-30 |
2013-10-30 |
Merck Sharp & Dohme |
In glycoengineerter pichia pastoris hergestellter granulozytenkolonienstimulierender faktor
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
US8420083B2
(en)
*
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
WO2011054030A1
(en)
|
2009-11-05 |
2011-05-12 |
Cephalon Australia Pty Ltd |
Treatment of cancer involving mutated kras or braf genes
|
KR20130055555A
(ko)
|
2009-11-19 |
2013-05-28 |
옥시레인 유케이 리미티드 |
효모 스트레인 생성용 포유류 유사 복합 n-글리칸들
|
US8722615B2
(en)
|
2009-12-02 |
2014-05-13 |
Acceleron Pharma, Inc. |
Compositions and methods for increasing serum half-life
|
CN113717286A
(zh)
|
2009-12-08 |
2021-11-30 |
Abbvie德国有限责任两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
EP2519642B1
(de)
*
|
2009-12-28 |
2017-10-25 |
DSM IP Assets B.V. |
Auf xylose wachsende rekombinante thraustochytride sowie zusammensetzungen, herstellungsverfahren und verwendungen davon
|
EP3505632B1
(de)
|
2009-12-28 |
2022-08-03 |
Sanofi Vaccine Technologies, S.A.S. |
Herstellung heterologer polypeptide in mikroalgen, extrazelluläre algenkörper, zusammensetzungen und verfahren zur herstellung sowie verwendungen davon
|
EP2519636B8
(de)
*
|
2009-12-28 |
2017-08-09 |
DSM IP Assets B.V. |
Herstellung eines hämagglutinin-neuraminidase-proteins in mikroalgen
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
EP2539430B1
(de)
*
|
2010-02-24 |
2016-09-14 |
Merck Sharp & Dohme Corp. |
Verfahren zur erhöhung der belegung von n-glycosylierungsstandorten mit in pichia pastoris produzierten glycoproteinen
|
MX348312B
(es)
|
2010-03-02 |
2017-06-06 |
Abbvie Inc |
Proteínas terapéuticas de enlace dll4.
|
MX2012011648A
(es)
|
2010-04-07 |
2012-11-29 |
Momenta Pharmaceuticals Inc |
Glicanos de alta manosa.
|
EP2558494B1
(de)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
JP6066900B2
(ja)
|
2010-04-26 |
2017-01-25 |
エータイアー ファーマ, インコーポレイテッド |
システイニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CN103096911B
(zh)
|
2010-04-27 |
2018-05-29 |
Atyr 医药公司 |
与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
AU2011248457B2
(en)
|
2010-04-29 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
EP2566515B1
(de)
|
2010-05-03 |
2017-08-02 |
aTyr Pharma, Inc. |
Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von arginyl-trna-synthetasen
|
AU2011248230B2
(en)
|
2010-05-03 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
|
JP6008844B2
(ja)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
KR101539684B1
(ko)
|
2010-05-14 |
2015-07-27 |
애브비 인코포레이티드 |
Il-1 결합 단백질
|
JP6396656B2
(ja)
|
2010-05-14 |
2018-09-26 |
エータイアー ファーマ, インコーポレイテッド |
フェニルアラニルβtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
NZ603883A
(en)
|
2010-05-27 |
2015-01-30 |
Merck Sharp & Dohme |
Method for preparing antibodies having improved properties
|
JP6046607B2
(ja)
|
2010-05-27 |
2016-12-21 |
エータイアー ファーマ, インコーポレイテッド |
グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
US8962560B2
(en)
|
2010-06-01 |
2015-02-24 |
Atyr Pharma Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN103118695B
(zh)
|
2010-07-12 |
2016-08-03 |
Atyr医药公司 |
与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
US20140308699A1
(en)
*
|
2010-07-30 |
2014-10-16 |
Glycode |
Yeast artificial chromosome carrying the mammalian glycosylation pathway
|
CN103298834A
(zh)
|
2010-08-03 |
2013-09-11 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
HRP20220405T1
(hr)
|
2010-08-19 |
2022-05-27 |
Zoetis Belgium S.A. |
Protutijela protiv ngf i njihova upotreba
|
US9029506B2
(en)
|
2010-08-25 |
2015-05-12 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP6151183B2
(ja)
|
2010-09-29 |
2017-06-21 |
オキシレイン ユーケー リミテッド |
マンノース−1−ホスホ−6−マンノース結合からキャップを外すことおよびリン酸化n−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法
|
JP6131190B2
(ja)
|
2010-09-29 |
2017-05-17 |
オキシレイン ユーケー リミテッド |
リン酸化n−グリカンの脱マンノシル化
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−il12rベータ1抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
CN103534392A
(zh)
|
2010-12-01 |
2014-01-22 |
默沙东公司 |
表面锚定的fc-诱饵抗体展示系统
|
US9458240B2
(en)
|
2010-12-10 |
2016-10-04 |
Novartis Pharma Ag |
Anti-BAFFR antibody formulations
|
CA2821976A1
(en)
|
2010-12-21 |
2012-09-13 |
Abbvie Inc. |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
WO2012109285A2
(en)
|
2011-02-08 |
2012-08-16 |
Medimmune, Llc |
Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
|
CA2827732A1
(en)
|
2011-02-25 |
2012-08-30 |
Merck Sharp & Dohme Corp. |
Yeast strain for the production of proteins with modified o-glycosylation
|
CN103782168B
(zh)
|
2011-03-12 |
2016-03-16 |
动量制药公司 |
在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
|
JP2014509864A
(ja)
|
2011-03-23 |
2014-04-24 |
グリコド |
Gdp−フコースを産生可能な酵母組換え細胞
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
WO2012156309A1
(en)
|
2011-05-13 |
2012-11-22 |
Millegen |
Antibodies against her3
|
US9328170B2
(en)
|
2011-05-25 |
2016-05-03 |
Merck Sharp & Dohme Corp. |
Method for preparing Fc containing polypeptides having improved properties
|
BR112013031762A2
(pt)
|
2011-06-16 |
2016-09-13 |
Novartis Ag |
proteínas solúveis para utilização como terapêuticos
|
FR2976811A1
(fr)
|
2011-06-22 |
2012-12-28 |
Lfb Biotechnologies |
Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
|
ES2677367T3
(es)
|
2011-06-22 |
2018-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticuerpos anti-Axl y usos de los mismos
|
KR20140104944A
(ko)
|
2011-06-22 |
2014-08-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-axl 항체 및 그의 용도
|
ES2692519T3
(es)
|
2011-07-01 |
2018-12-04 |
Novartis Ag |
Método para tratar trastornos metabólicos
|
EP3574919A1
(de)
|
2011-07-13 |
2019-12-04 |
AbbVie Inc. |
Verfahren und zusammensetzungen zur behandlung von asthma mit anti-il-13-antikörpern
|
BR112014001120A2
(pt)
|
2011-07-20 |
2017-02-21 |
Zepteon Incorporated |
métodos de separação de polipeptídeos
|
EP2765194B1
(de)
*
|
2011-10-03 |
2017-12-20 |
National Institute of Advanced Industrial Science and Technology |
Komplexe zuckerkettenhydrolase
|
CN104203978A
(zh)
|
2011-10-24 |
2014-12-10 |
艾伯维股份有限公司 |
针对硬化蛋白的免疫结合剂
|
JP2014534218A
(ja)
|
2011-10-24 |
2014-12-18 |
アッヴィ・インコーポレイテッド |
Tnfを標的とする免疫結合剤
|
US9328367B2
(en)
|
2011-10-28 |
2016-05-03 |
Merck Sharp & Dohme Corp. |
Engineered lower eukaryotic host strains for recombinant protein expression
|
WO2013059885A2
(en)
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
WO2013066685A1
(en)
*
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Engineered pichia strains with improved fermentation yield and n-glycosylation quality
|
JP2014533249A
(ja)
|
2011-11-07 |
2014-12-11 |
メディミューン,エルエルシー |
多重特異性を持つ多価結合タンパク質およびその使用
|
KR101457514B1
(ko)
*
|
2011-11-21 |
2014-11-03 |
한국생명공학연구원 |
우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
|
US9573987B2
(en)
|
2011-12-20 |
2017-02-21 |
Indiana University Research And Technology Corporation |
CTP-based insulin analogs for treatment of diabetes
|
JP2015508994A
(ja)
|
2011-12-30 |
2015-03-26 |
アッヴィ・インコーポレイテッド |
Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
|
EP2617732A1
(de)
|
2012-01-19 |
2013-07-24 |
Vib Vzw |
Werkzeuge und Verfahren zur Expression von Membranproteinen
|
US20130330347A1
(en)
|
2012-01-27 |
2013-12-12 |
Abbvie Inc. |
Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
|
RU2659423C2
(ru)
|
2012-02-16 |
2018-07-02 |
ЭйТИР ФАРМА, ИНК. |
ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
|
EP3628326B1
(de)
|
2012-03-15 |
2024-02-28 |
Oxyrane UK Limited |
Verfahren und materialien zur behandlung von morbus pompe
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9890378B2
(en)
|
2012-05-11 |
2018-02-13 |
Merck Sharp & Dohme Corp. |
Surface anchored light chain bait antibody display system
|
WO2013174927A1
(en)
|
2012-05-23 |
2013-11-28 |
Novartis International Pharmaceutical Limited |
Production of fucosylated glycoproteins
|
US9695244B2
(en)
|
2012-06-01 |
2017-07-04 |
Momenta Pharmaceuticals, Inc. |
Methods related to denosumab
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ngf抗体およびその方法
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
EP2874658A1
(de)
|
2012-07-18 |
2015-05-27 |
Glycotope GmbH |
Neue therapeutische behandlungen mit anti-her2-antikörpern mit geringer fucosylierung
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
WO2014066134A1
(en)
|
2012-10-22 |
2014-05-01 |
Merck Sharp & Dohme Corp. |
Crz1 mutant fungal cells
|
AU2013334652B2
(en)
|
2012-10-23 |
2019-02-21 |
Research Corporation Technologies, Inc. |
Pichia pastoris strains for producing predominantly homogeneous glycan structure
|
US20150246118A1
(en)
|
2012-10-26 |
2015-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
RU2636043C2
(ru)
|
2012-11-01 |
2017-11-17 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
EP2733153A1
(de)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
|
US9707276B2
(en)
|
2012-12-03 |
2017-07-18 |
Merck Sharp & Dohme Corp. |
O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
|
WO2014093240A1
(en)
|
2012-12-10 |
2014-06-19 |
The General Hospital Corporation |
Bivalent il-2 fusion toxins
|
WO2014090948A1
(en)
|
2012-12-13 |
2014-06-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serpin spn4a and biologically active derivatives thereof for use in the treatment of cancer
|
EP2931749B1
(de)
|
2012-12-17 |
2019-04-24 |
Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme |
Verwendung monoklonaler antikörper zur behandlung von entzündungen und bakteriellen infektionen
|
WO2014100139A1
(en)
|
2012-12-18 |
2014-06-26 |
The Rockefeller University |
Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
EP2938636A2
(de)
|
2012-12-28 |
2015-11-04 |
AbbVie Inc. |
Effizientes system und verfahren zur identifikation von antikörpern mit spezifischer antigenbindender wirkung
|
KR20160002681A
(ko)
|
2013-01-16 |
2016-01-08 |
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) |
골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
|
EP2948177A1
(de)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Verfahren zur optimierung der domänenstabilität von bindungsproteinen
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
SG11201505330QA
(en)
|
2013-02-08 |
2015-08-28 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
US9534041B2
(en)
|
2013-02-12 |
2017-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that neutralize a norovirus
|
CN105308068A
(zh)
|
2013-02-13 |
2016-02-03 |
法国化学与生物科技实验室 |
高度半乳糖基化的抗TNF-α抗体及其用途
|
WO2014138188A1
(en)
|
2013-03-07 |
2014-09-12 |
The General Hospital Corporation |
Human ctla4 mutants and use thereof
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
EP2970398B1
(de)
|
2013-03-13 |
2024-05-08 |
The United States of America, as Represented by The Secretary, Department of Health and Human Services |
Rsv-f-prefusionsproteine und deren verwendung
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
EP2971046A4
(de)
|
2013-03-14 |
2016-11-02 |
Abbott Lab |
Monoklonale antikörper gegen hcv-core lipid-bindender domäne
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
BR112015023071A2
(pt)
|
2013-03-14 |
2017-07-18 |
Univ Indiana Res & Tech Corp |
conjugados de insulina-incretina
|
CN114717206A
(zh)
|
2013-03-15 |
2022-07-08 |
Atyr 医药公司 |
组氨酰-trna合成酶-fc缀合物
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
EP2855533A4
(de)
|
2013-03-15 |
2015-11-25 |
Momenta Pharmaceuticals Inc |
Verfahren in zusammenhang mit ctla4-fc-fusionsproteinen
|
WO2014173886A1
(en)
|
2013-04-22 |
2014-10-30 |
Glycotope Gmbh |
Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
|
CN110526971B
(zh)
|
2013-04-29 |
2023-06-30 |
泰华制药澳大利亚公司 |
抗-CD38抗体和与致弱干扰素α-2B的融合体
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
WO2014183052A1
(en)
|
2013-05-09 |
2014-11-13 |
The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services |
Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
|
EP2996772B1
(de)
|
2013-05-13 |
2018-12-19 |
Momenta Pharmaceuticals, Inc. |
Verfahren zur behandlung von neurodegeneration
|
EP3033358A2
(de)
|
2013-08-14 |
2016-06-22 |
Novartis AG |
Verfahren zur behandlung sporadischer einschlusskörper-myositis
|
WO2015032899A1
(en)
|
2013-09-05 |
2015-03-12 |
Vib Vzw |
Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof
|
WO2015044379A1
(en)
|
2013-09-27 |
2015-04-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A dyrk1a polypeptide for use in preventing or treating metabolic disorders
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN113667013B
(zh)
|
2013-10-02 |
2024-04-09 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US20160257754A1
(en)
|
2013-10-16 |
2016-09-08 |
Momenta Pharmaceuticals Inc. |
Sialylated glycoproteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US10988745B2
(en)
|
2013-10-31 |
2021-04-27 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
US10196455B2
(en)
|
2013-11-07 |
2019-02-05 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Neuregulin allosteric anti-HER3 antibody
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
FR3016633B1
(fr)
|
2014-01-17 |
2018-04-13 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Immunoglobuline anti-toxine du charbon
|
EP3495482B1
(de)
|
2014-01-21 |
2020-09-02 |
Synplogen Co., Ltd. |
Verfahren zur vorbereitung einer dna-einheit-zusammensetzung und verfahren zur erzeugung von verketteter dna
|
CA2942101A1
(en)
|
2014-03-21 |
2015-09-24 |
Abbvie Inc. |
Anti-egfr antibodies and antibody drug conjugates
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
CN113173990A
(zh)
|
2014-07-15 |
2021-07-27 |
免疫医疗有限责任公司 |
中和抗乙型流感抗体及其用途
|
CA2954974A1
(en)
|
2014-07-21 |
2016-01-28 |
Glykos Finland Oy |
Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
TWI790593B
(zh)
|
2014-08-19 |
2023-01-21 |
美商默沙東有限責任公司 |
抗tigit抗體
|
CN108271356A
(zh)
|
2014-09-24 |
2018-07-10 |
印第安纳大学研究及科技有限公司 |
肠降血糖素-胰岛素缀合物
|
WO2016050867A1
(en)
|
2014-10-01 |
2016-04-07 |
Medimmune Limited |
Antibodies to ticagrelor and methods of use
|
US10544199B2
(en)
|
2014-10-29 |
2020-01-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon alpha 2B variants
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
MX2017006127A
(es)
|
2014-11-11 |
2017-11-08 |
Clara Foods Co |
Metodos y composiciones para produccion de proteina de clara de huevo.
|
US10072070B2
(en)
|
2014-12-05 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent anti-influenza A neuraminidase subtype N1 antibody
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
JP6770533B2
(ja)
|
2015-05-22 |
2020-10-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Cath−Dの触媒活性と、そのLRP1レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
|
AR104809A1
(es)
|
2015-05-29 |
2017-08-16 |
Abbvie Inc |
Anticuerpos anti-cd40 y usos de los mismos
|
SI3303384T1
(sl)
|
2015-06-01 |
2021-11-30 |
Medimmune Llc |
Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
EP3320105B1
(de)
|
2015-07-09 |
2021-03-10 |
Vib Vzw |
Zellen mit herstellung von glycoproteinen mit veränderten n- und o-glycosylierungs-mustern und verfahren und verwendung davon
|
EP3356415B1
(de)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr-inhibitoren
|
NZ741573A
(en)
|
2015-10-12 |
2019-11-29 |
Aprogen Kic Inc |
Anti-cd43 antibody and use thereof for cancer treatment
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
KR20180086502A
(ko)
|
2015-12-16 |
2018-07-31 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항원-결합 단편
|
CN108495653A
(zh)
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
CN109195993B
(zh)
|
2016-02-06 |
2022-05-10 |
岸迈生物科技有限公司 |
串联fab免疫球蛋白及其用途
|
CN108699142A
(zh)
|
2016-02-17 |
2018-10-23 |
诺华股份有限公司 |
TGFβ2抗体
|
CN114907483A
(zh)
|
2016-03-22 |
2022-08-16 |
国家医疗保健研究所 |
人源化抗claudin-1抗体及其用途
|
IL300274A
(en)
|
2016-06-08 |
2023-04-01 |
Abbvie Inc |
Antibodies against B7–H3 and conjugates of drug and antibody
|
US20190153107A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
US20190153108A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
TW202320860A
(zh)
|
2016-06-08 |
2023-06-01 |
美商艾伯維有限公司 |
抗egfr抗體藥物結合物
|
JP2019524649A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
AU2017277914A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
WO2018005954A2
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
CA3030926A1
(en)
|
2016-07-19 |
2018-01-25 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd47 combination therapy
|
KR102487356B1
(ko)
|
2016-07-29 |
2023-01-12 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
종양 관련 대식세포를 표적화하는 항체 및 이의 용도
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
WO2018026969A2
(en)
|
2016-08-03 |
2018-02-08 |
Achaogen, Inc. |
Plazomicin antibodies and methods of use
|
WO2018035084A1
(en)
|
2016-08-16 |
2018-02-22 |
Epimab Biotherapeutics, Inc. |
Monovalent asymmetric tandem fab bispecific antibodies
|
CN109863171B
(zh)
|
2016-08-23 |
2023-08-04 |
免疫医疗有限公司 |
抗vegf-a和抗ang2抗体及其用途
|
EP3783022A3
(de)
|
2016-08-23 |
2021-06-30 |
MedImmune Limited |
Anti-vegf-a-antikörper und verwendungen davon
|
EP3512883A1
(de)
|
2016-09-13 |
2019-07-24 |
Humanigen, Inc. |
Epha3-antikörper zur behandlung von lungenfibrose
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
CN110121508A
(zh)
|
2016-10-25 |
2019-08-13 |
法国国家健康和医学研究院 |
与cd160跨膜同种型结合的单克隆抗体
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
PE20190921A1
(es)
|
2016-12-07 |
2019-06-26 |
Agenus Inc |
Anticuerpos y metodos de su utilizacion
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
US11883434B2
(en)
|
2017-03-15 |
2024-01-30 |
Nutech Ventures |
Extracellular vesicles and methods of using
|
WO2018175460A1
(en)
|
2017-03-24 |
2018-09-27 |
Novartis Ag |
Methods for preventing and treating heart disease
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
MX2019012233A
(es)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anticuerpos anti-sirpa.
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
US20200148777A1
(en)
|
2017-05-29 |
2020-05-14 |
Gamamabs Pharma |
Cancer-associated immunosuppression inhibitor
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
US11898187B2
(en)
|
2017-08-15 |
2024-02-13 |
Northwestern University |
Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
|
CA3073537A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
JP7437301B2
(ja)
|
2017-08-25 |
2024-02-22 |
ファイヴ プライム セラピューティクス インク |
B7-h4抗体及びその使用方法
|
EP3694552A1
(de)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap-antikörper und verwendungen davon
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CA3091174A1
(en)
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody formulations
|
EP3755719A1
(de)
|
2018-02-21 |
2020-12-30 |
Five Prime Therapeutics, Inc. |
B7-h4-antikörperdosierschemata
|
SG11202008105RA
(en)
|
2018-03-02 |
2020-09-29 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
KR20200130696A
(ko)
|
2018-03-12 |
2020-11-19 |
조에티스 서비시즈 엘엘씨 |
항-ngf 항체 및 이의 방법
|
US11530432B2
(en)
|
2018-03-19 |
2022-12-20 |
Northwestern University |
Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
|
US11725224B2
(en)
|
2018-04-16 |
2023-08-15 |
Northwestern University |
Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
|
JP2021534763A
(ja)
*
|
2018-08-21 |
2021-12-16 |
クララ フーズ カンパニー |
微生物におけるタンパク質のグリコシル化の修飾
|
WO2020056077A1
(en)
|
2018-09-13 |
2020-03-19 |
The Board Of Regents Of The University Of Texas System |
Novel lilrb4 antibodies and uses thereof
|
EP3853251A1
(de)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von krebserkrankungen mit resistenz gegen immun-checkpoint-therapie
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
CA3114955A1
(en)
|
2018-10-15 |
2020-04-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
US20220025058A1
(en)
|
2018-11-06 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
US20220064260A1
(en)
|
2018-12-14 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
EP3906062A1
(de)
|
2019-01-04 |
2021-11-10 |
Resolve Therapeutics, LLC |
Behandlung von sjögren-krankheit mit nukleasefusionsproteinen
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
US20220251232A1
(en)
|
2019-05-20 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
UY38747A
(es)
|
2019-06-12 |
2021-01-29 |
Novartis Ag |
Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
|
KR20220034848A
(ko)
|
2019-07-11 |
2022-03-18 |
클라라 푸드즈 컴퍼니 |
단백질 조성물 및 이의 섭취 가능한 제품
|
JP2022541200A
(ja)
|
2019-07-16 |
2022-09-22 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
Cd38に特異性を有する抗体及びその使用
|
US10927360B1
(en)
|
2019-08-07 |
2021-02-23 |
Clara Foods Co. |
Compositions comprising digestive enzymes
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
EP4093760A1
(de)
|
2020-01-21 |
2022-11-30 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd |
Verwendung von pflanzenproteinhomologen in kulturmedien
|
US20230061973A1
(en)
|
2020-02-05 |
2023-03-02 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
KR20230017207A
(ko)
|
2020-04-30 |
2023-02-03 |
사이로파 비.브이. |
항-cd103 항체
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
MX2022014422A
(es)
|
2020-05-17 |
2022-12-07 |
Astrazeneca Uk Ltd |
Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
|
MX2022016322A
(es)
|
2020-06-25 |
2023-01-24 |
Merck Sharp & Dohme Llc |
Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
|
WO2022006153A1
(en)
|
2020-06-29 |
2022-01-06 |
Resolve Therapeutics, Llc |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
US20220041694A1
(en)
|
2020-08-10 |
2022-02-10 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies for treatment and prevention of covid-19
|
CA3199006A1
(en)
|
2020-11-20 |
2022-05-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-cd25 antibodies
|
JP2024504547A
(ja)
|
2020-11-20 |
2024-02-01 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
抗cd25抗体
|
US20240052042A1
(en)
|
2020-12-14 |
2024-02-15 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
|
CN116710482A
(zh)
|
2021-01-08 |
2023-09-05 |
北京韩美药品有限公司 |
特异性结合4-1bb的抗体及其抗原结合片段
|
WO2022148412A1
(zh)
|
2021-01-08 |
2022-07-14 |
北京韩美药品有限公司 |
特异性结合cd47的抗体及其抗原结合片段
|
CN116670290A
(zh)
|
2021-01-08 |
2023-08-29 |
北京韩美药品有限公司 |
特异性结合pd-l1的抗体及其抗原结合片段
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
EP4313317A1
(de)
|
2021-03-23 |
2024-02-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur diagnose und behandlung von t-zelllymphomen
|
EP4320153A1
(de)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von anaplastischem grosszelligem lymphom
|
TW202306989A
(zh)
|
2021-06-22 |
2023-02-16 |
瑞士商諾華公司 |
用於在治療化膿性汗腺炎中使用的雙特異性抗體
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
EP4186529A1
(de)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
TW202405009A
(zh)
|
2022-03-30 |
2024-02-01 |
瑞士商諾華公司 |
使用抗利尿鈉肽受體1(npr1)抗體治療障礙之方法
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
CN115386009B
(zh)
*
|
2022-04-26 |
2023-12-01 |
江苏靶标生物医药研究所有限公司 |
一种膜联蛋白v与血管生成抑制剂融合蛋白的构建方法和应用
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
EP4309666A1
(de)
|
2022-07-21 |
2024-01-24 |
Technische Universität Dresden |
M-csf zur verwendung bei der prophylaxe und/oder behandlung viraler infektionen bei immunsuppressionszuständen
|
WO2024017998A1
(en)
|
2022-07-21 |
2024-01-25 |
Technische Universität Dresden |
M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
CN115590017B
(zh)
*
|
2022-11-04 |
2023-09-12 |
中国农业大学 |
一种通过降低线粒体温度提高卵母细胞冷冻效果的方法
|